After the warrant contribution, Ascelia Pharma is well funded for 2025 with some SEK 80m net cash, which is enough for securing a partner ahead of the US launch in 2026 and completing the submission of Orviglance by the first half of August. If Ascelia can secure a strong US partner on good terms, our Base Case target price could be reached within three to twelve months.
LÄS MER
